Rekah Pharmaceutical Industry Ltd (REKA) - Total Liabilities
Based on the latest financial reports, Rekah Pharmaceutical Industry Ltd (REKA) has total liabilities worth ILA279.47 Million ILA (≈ $749.25K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore REKA net assets growth trend to track the company's year-over-year net asset growth rate.
Rekah Pharmaceutical Industry Ltd - Total Liabilities Trend (2004–2025)
This chart illustrates how Rekah Pharmaceutical Industry Ltd's total liabilities have evolved over time, based on quarterly financial data. See REKA free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Rekah Pharmaceutical Industry Ltd Competitors by Total Liabilities
The table below lists competitors of Rekah Pharmaceutical Industry Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dierig Holding AG
XETRA:DIE
|
Germany | €76.08 Million |
|
Smart Logistics Global Limited Ordinary Shares
NASDAQ:SLGB
|
USA | $59.43 Million |
|
Comms Group Ltd
AU:CCG
|
Australia | AU$31.35 Million |
|
SHL Telemedicine Ltd American Depositary Shares
NASDAQ:SHLT
|
USA | $41.51 Million |
|
Beauty Community Public Company Limited
BK:BEAUTY
|
Thailand | ฿81.31 Million |
|
Mepet Metro Petrol ve Tesisleri Sanayi Ticaret AS
IS:MEPET
|
Turkey | TL529.31 Million |
|
Wellbiotec Co. Ltd.
KO:010600
|
Korea | ₩11.76 Billion |
|
Q linea AB
ST:QLINEA
|
Sweden | Skr29.06 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Rekah Pharmaceutical Industry Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Rekah Pharmaceutical Industry Ltd (REKA) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rekah Pharmaceutical Industry Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rekah Pharmaceutical Industry Ltd (2004–2025)
The table below shows the annual total liabilities of Rekah Pharmaceutical Industry Ltd from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ILA279.47 Million ≈ $749.25K |
-2.02% |
| 2024-12-31 | ILA285.24 Million ≈ $764.73K |
-13.34% |
| 2023-12-31 | ILA329.14 Million ≈ $882.40K |
+14.95% |
| 2022-12-31 | ILA286.34 Million ≈ $767.66K |
+8.45% |
| 2021-12-31 | ILA264.02 Million ≈ $707.84K |
+3.91% |
| 2020-12-31 | ILA254.10 Million ≈ $681.23K |
+19.92% |
| 2019-12-31 | ILA211.89 Million ≈ $568.08K |
+41.62% |
| 2018-12-31 | ILA149.62 Million ≈ $401.13K |
-0.47% |
| 2017-12-31 | ILA150.33 Million ≈ $403.02K |
-30.68% |
| 2016-12-31 | ILA216.86 Million ≈ $581.40K |
+8.34% |
| 2015-12-31 | ILA200.17 Million ≈ $536.64K |
-14.11% |
| 2014-12-31 | ILA233.05 Million ≈ $624.81K |
+4.21% |
| 2013-12-31 | ILA223.65 Million ≈ $599.59K |
-1.43% |
| 2012-12-31 | ILA226.90 Million ≈ $608.32K |
+1.76% |
| 2011-12-31 | ILA222.98 Million ≈ $597.81K |
-0.54% |
| 2010-12-31 | ILA224.18 Million ≈ $601.03K |
+4.64% |
| 2009-12-31 | ILA214.25 Million ≈ $574.39K |
-7.60% |
| 2008-12-31 | ILA231.87 Million ≈ $621.64K |
-0.85% |
| 2007-12-31 | ILA233.86 Million ≈ $626.98K |
-0.48% |
| 2006-12-31 | ILA234.99 Million ≈ $630.01K |
+12.90% |
| 2005-12-31 | ILA208.15 Million ≈ $558.04K |
+35.89% |
| 2004-12-31 | ILA153.18 Million ≈ $410.66K |
-- |
About Rekah Pharmaceutical Industry Ltd
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products. Its portfolio of products comprise Rx and OTC drugs, and medical devices used in various therapeut… Read more